Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2020-12-09 Sale |
2020-12-10 6:19 pm |
JOHNSON & JOHNSON | JNJ | Sneed Michael E EVP, Global Corp Aff & COO |
54,662 | $152.93 | $8,359,460 | 59,956 (Indirect Direct) |
View |
| 2020-09-02 Sale |
2020-09-04 2:58 pm |
JOHNSON & JOHNSON | JNJ | Wengel Kathryn E EVP, Chief GSC Officer |
16,115 | $153.52 | $2,473,938 | 58,736 (Indirect Direct) |
View |
| 2020-07-28 Sale |
2020-07-28 6:43 pm |
JOHNSON & JOHNSON | JNJ | McEvoy Ashley EVP, WW Chair, Medical Devices |
29,000 | $147.47 | $4,276,630 | 24,433 (Indirect Direct) |
View |
| 2020-06-30 Purchase |
2020-07-02 4:58 pm |
Fusion Pharmaceuticals Inc. | FUSN | JOHNSON & JOHNSON Johnson & Johnson Innovation - JJDC Inc. 10% Owner |
725,000 | $17 | $12,325,000 | 3,759,634 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2020-12-08 Option Award |
2020-12-10 6:20 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Washington A. Eugene Director |
355 | $149.21 | 23,078 (Direct) |
View |
| 2020-12-08 Option Award |
2020-12-10 6:19 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | HEWSON MARILLYN A Director |
214 | $149.21 | 2,089 (Direct) |
View |
| 2020-12-09 Exercise |
2020-12-10 6:19 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Sneed Michael E EVP, Global Corp Aff & COO |
54,662 | $62.2 | 59,956 (Direct) |
View |
| 2020-12-09 Exercise |
2020-12-10 6:19 pm |
2014-01-11 2021-01-08 |
JOHNSON & JOHNSON | JNJ | Sneed Michael E EVP, Global Corp Aff & COO |
54,662 | $0 | 59,956 (Direct) |
View |
| 2020-09-08 Option Award |
2020-09-10 4:58 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | WEINBERGER MARK A Director |
213 | $0 | 1,875 (Direct) |
View |
| 2020-09-08 Option Award |
2020-09-10 4:58 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Washington A. Eugene Director |
353 | $0 | 22,723 (Direct) |
View |
| 2020-09-08 Option Award |
2020-09-10 4:58 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | HEWSON MARILLYN A Director |
213 | $0 | 1,875 (Direct) |
View |
| 2020-09-02 Exercise |
2020-09-04 2:58 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Wengel Kathryn E EVP, Chief GSC Officer |
8,238 | $62.2 | 58,736 (Direct) |
View |
| 2020-09-02 Exercise |
2020-09-04 2:58 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Wengel Kathryn E EVP, Chief GSC Officer |
7,877 | $65.37 | 58,736 (Direct) |
View |
| 2020-09-02 Exercise |
2020-09-04 2:58 pm |
2014-01-11 2021-01-08 |
JOHNSON & JOHNSON | JNJ | Wengel Kathryn E EVP, Chief GSC Officer |
16,115 | $0 | 58,736 (Direct) |
View |
| 2020-06-30 Conversion |
2020-07-02 4:58 pm |
N/A N/A |
Fusion Pharmaceuticals Inc. | FUSN | JOHNSON & JOHNSON Johnson & Johnson Innovation - JJDC Inc. 10% Owner |
19,236,563 | $0 | 3,759,634 (Indirect) |
View |
Ownership |
2020-06-25 8:10 pm |
N/A N/A |
Fusion Pharmaceuticals Inc. | FUSN | JOHNSON & JOHNSON Johnson & Johnson Innovation - JJDC Inc. 10% Owner |
0 | $0 | 3,034,634 (Indirect) |
View |
| 2020-06-09 Option Award |
2020-06-11 4:22 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | WEINBERGER MARK A Director |
214 | $0 | 1,662 (Direct) |
View |
| 2020-06-09 Option Award |
2020-06-11 4:20 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | Washington A. Eugene Director |
356 | $0 | 22,370 (Direct) |
View |
| 2020-06-09 Option Award |
2020-06-11 4:11 pm |
N/A N/A |
JOHNSON & JOHNSON | JNJ | HEWSON MARILLYN A Director |
214 | $0 | 1,662 (Direct) |
View |